ISRCTN15135908 https://doi.org/10.1186/ISRCTN15135908

# A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque Psoriasis

**Submission date**
03/08/2022

**Recruitment status**
No longer recruiting

**Registration date**
11/10/2022

**Overall study status**
Completed

**Last Edited**
09/08/2024

**Condition category**
Skin and Connective Tissue Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

## Plain English summary of protocol

Background and study aims
Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union, and Japan. Despite advanced treatment options, large numbers of patients are not receiving these therapies. There is a need for safer options, fewer injections, and more effective oral medications. Janssen has an investigational drug called JNJ-77242113, which targets immune responses in the body and skin that impact diseases, such as psoriasis. It is hoped that targeting immune response processes may lead to less inflammation and a reduction in psoriasis disease activity.

This study is a follow-on trial of 77242113PSO2001 (https://www.isrctn.com/ISRCTN76915275), which is designed to evaluate long-term efficacy and safety of the investigational drug JNJ-77242113 in adults with moderate to severe plaque psoriasis.

Who can participate?
Patients who have completed the week 16 weeks in the study 77242113PSO2001 and who, in the opinion of the investigator, may benefit from inclusion in this long-term extension study.

What does the study involve?
This is a long-term extension study of JNJ-77242113 in eligible participants who completed the Week 16 visit of the originating 77242113PSO2001 study. All participants will receive active JNJ-77242113 study medication. The total study duration will be up to 40 weeks which will include:
1. A 36-week treatment period
2. A 4-week safety follow-up period after the last study intervention administration

Safety will be assessed by clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs, physical examinations, and monitoring adverse events (AEs) throughout the study.

What are the possible benefits and risks of participating?
Possible benefits for patients taking JNJ-77242113 include improvements in plaque psoriasis symptoms based on current scientific theory. Only patients who may benefit from such drug

treatment (i.e., with specific disease characteristics identified by study investigators) are eligible for study inclusion. Such patient participation may help other psoriasis patients in the future.

Study participants also may experience some benefits not due to receiving the study drug, but instead due to regular visits, assessments, and overall health monitoring. Long-term benefits, however, are not guaranteed to happen and there may not be any benefit to participants by being in this study.

Not all possible side effects and risks related to JNJ-77242113 are known, such that unexpected side effects may arise or be life-threatening.

A participant information sheet (which will be signed by every participant agreeing to participate in the study) includes a detailed section outlining all known risks/side effects to study participants.

To minimize any study-associated risks participants are frequently reviewed at every visit for side effects and adverse events and participants are educated to report any such problems to the study staff without delay.

Any serious adverse events that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team and the sponsor has implemented an Independent Data Review Committee.

Where is the study run from?
Janssen-Cilag International NV (Belgium) is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for?
June 2022 to November 2023

Who is funding the study?
Janssen Research and Development, LLC (USA)

Who is the main contact?
Sarah Currie, JanssenUKRegistryQueries@its.jnj.com

# Contact information

### Type(s)
Scientific

### Contact name
Dr Medical Information and Product Information Enquiry

### Contact details
50-100 Holmers Farm Way
High Wycombe
United Kingdom
HP12 4DP
+44 (0)800 731 8450
medinfo@its.jnj.com

### Type(s)
Principal Investigator

### Contact name
Dr Andrew Pink

### Contact details
Guy's Hospital
Great Maze Pond
London
United Kingdom
London

# Additional identifiers

### EudraCT/CTIS number
2021-004320-16

### IRAS number
1005014

### ClinicalTrials.gov number
NCT05364554

### Secondary identifying numbers
IRAS 1005014, 77242113PSO2002, CPMS 52237

# Study information

### Scientific Title
A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis.

### Acronym
FRONTIER 2

### Study objectives
Main objectives:
1. To evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis

Secondary objectives:
1. To evaluate and assess additional long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis
2. To evaluate and assess the effect of JNJ-77242113 treatment on patient-reported psoriasis severity in participants with moderate-to-severe plaque psoriasis
3. To evaluate and assess the safety and tolerability of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Approved 03/08/2022, South Central - Berkshire B Research Ethics Committee (Meeting held by video-conference via Zoom; +44 (0)207 104 8253, +44 (0)207 104 8068, +44 (0)207 104 8276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0224

## Study design
Multicentre, long-term extension, double-blind, dose-ranging, parallel group, randomized interventional study

## Primary study design
Interventional

## Secondary study design
Randomised controlled trial

## Study setting(s)
Hospital

## Study type(s)
Treatment

## Participant information sheet
No participant information sheet provided

## Health condition(s) or problem(s) studied
Plaque psoriasis

## Interventions
The total duration of this study is up to 40 weeks which includes a 36-week treatment period, and a 4-week safety follow-up period. Participants will continue to receive the dose randomly assigned by the online interactive web randomisation system tool from the preceding study (77242113PSO2001).

Those participants assigned to the placebo treatment arm in the preceding study will be assigned to an active treatment arm in this study. Each active cohort group will also receive placebo to maintain blinding of dose regimens throughout the trial:
1. Group 1 will receive dose 1 of JNJ-77242113 once daily and placebo
2. Group 2 will receive dose 2 of JNJ-77242113 once daily and placebo
3. Group 3 will receive dose 3 of JNJ-77242113 once daily and placebo
4. Group 4 will receive dose 1 of JNJ-77242113 twice daily and placebo
5. Group 5 will receive dose 3 of JNJ-77242113 twice daily and placebo
6. Group 6 will receive dose 3 of JNJ-77242113 once daily and placebo

## Intervention Type
Drug

## Phase
Phase II

## Drug/device/biological/vaccine name(s)
JNJ-77242113

## Primary outcome measure
Percentage of participants achieving Psoriasis Area Severity Index (PASI) 75 score (≥75% improvement in PASI from baseline of the originating study [77242113PSO2001]) at Week 36. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

## Secondary outcome measures
1. Percentage of participants achieving PASI 90 score (≥90% improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
2. Percentage of participants achieving PASI 100 score (≥100% improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
3. Change from baseline of the originating study (77242113PSO2001) in PASI Total Score at Week 36
4. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) determined at Week 36. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
5. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores reported at Week 36. The PSSD includes a patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
6. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Signs Scores reported at Week 36
7. Percentage of participants achieving PSSD Symptoms Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) symptoms score ≥1
8. Percentage of participants achieving PSSD Signs Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) signs score ≥1
9. Number of participants with Adverse Events (AEs) monitored up to Week 40. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
10. Number of participants with Serious Adverse Events (SAEs) monitored up to Week 40. SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

### Overall study start date
14/06/2022

### Completion date
13/11/2023

## Eligibility

### Key inclusion criteria
1. Must have completed the Week 16 visit in Protocol 77232114PSO2001
2. In the opinion of the investigator, may benefit from inclusion in this long-term extension (LTE) study
3. Must agree to avoid prolonged sun exposure and avoid the use of tanning booths or other ultraviolet light sources during the study
4. Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or Investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention.
5. Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of the study intervention

### Participant type(s)
Patient

### Age group
Adult

### Sex
Both

### Target number of participants
240

### Total final enrolment
227

### Key exclusion criteria
1. Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason
2. Has received any biologic therapy or experimental therapy since completion of the originating study 77242113PSO2001
3. Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention
4. Has received the bacille Clamette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention
5. Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (antiHCV) positive, or has another clinically active liver disease, or tests positive for HBsAg or anti-HCV

### Date of first enrolment
10/06/2022

**Date of final enrolment**
06/02/2023

# Locations

**Countries of recruitment**
Canada

France

Germany

Japan

Korea, South

Poland

Spain

Taiwan

United Kingdom

United States of America

**Study participating centre**
**Innovaderm Research Inc.**
3530 boulevard Saint-Laurent
Montreal
Canada
H2H2B5

**Study participating centre**
**Skin Centre for Dermatology**
775 Monaghan Road
Peterborough
Canada
K9J 5K2

**Study participating centre**
**Dr. Chih-ho Hong Medical Inc.**
15300 105 Ave

Surrey
Canada
V3R 6A7

**Study participating centre**
**DermEdge Research**
333 Lakeshore Road West
Mississauga
Canada
L4Y 4C5

**Study participating centre**
**K. Papp Clinical Research**
135 Union Street East
Waterloo
Canada
N2J 1C4

**Study participating centre**
**Dermatology Research Institute Inc.**
8500 Blackfoot Trail SE
Calgary
Canada
T2J 7E1

**Study participating centre**
**XLR8 Medical Research**
2425 Tecumseh Road East
Windsor
Canada
N8W 1E6

**Study participating centre**
**Dermatrials Research**
25 Charlton Avenue East
Hamilton
Canada
L8N 1Y2

**Study participating centre**
**Universitatsklinikum Carl Gustav Carcus Dresden**
Fetscherstr. 74
Dresden
Germany
1307

**Study participating centre**
**MensingDerma research GmbH**
Heegbarg 4
Hamburg
Germany
22391

**Study participating centre**
**Universitatsklinikum Schleswig-Holstein - Kiel**
Arnold-Heller-Str. 3, Haus 19
Kiel
Germany
24105

**Study participating centre**
**Praxis für Dermatologie und Venerologie**
Hauptstrasse 36a
Dresden
Germany
1097

**Study participating centre**
**Rothhaar Studien GmbH**
Dermatologisches Studienzentrum
Berlin
Germany
10783

**Study participating centre**
**Hautarztpraxis**
Annenstraße 151
Witten
Germany
58453

**Study participating centre**
**Uniklinik Münster -Klinik u. Pol. f. Hautkrankheiten**
Von-Esmarch-Straße 58
Munster
Germany
48149

**Study participating centre**
**Niesmann & Othlinghaus GbR**
Alleestraße 80
Bochum
Germany
44793

**Study participating centre**
**Universitatsklinikum Frankfurt**
Theodor-Stern-Kai 7
Frankfurt am Main
Germany
60590

**Study participating centre**
**Universitätsklinikum Heidelberg Im Neuenheimer**
Feld 440
Heidelberg
Germany
69120

**Study participating centre**
**Gemeinschaftspraxis Scholz/Sebastian/Schilling**
Am Bahnhof 1
Mahlow
Germany
15831

**Study participating centre**
**ISA - Interdisciplinary Study Association GmbH**
Rankestrasse 34

Berlin
Germany
10789

**Study participating centre**
**Universitätsmedizin der Johannes Gutenberg-Universität Mainz**
Langenbeckstrasse 1
Mainz
Germany
55131

**Study participating centre**
**Fachklinik Bad Bentheim**
Am Bade 1
Bad Bentheim
Germany
48455

**Study participating centre**
**Rosenpark Research GmbH**
Rheinstrasse 14
Darmstadt
Germany
64283

**Study participating centre**
**Universitatsklinikum Bonn**
Klinik und Poliklinik für Dermatologie und Allergologie
Bonn
Germany
53127

**Study participating centre**
**Derma-Study-Center Friedrichshafen GmbH**
Charlottenstrasse 12/1
Friedrichshafen
Germany
88045

**Study participating centre**
**Hosp. Univ. I Politecni La Fe**
106 Avinguda de Fernando Abril Martorell
Valencia
Spain
46026

**Study participating centre**
**Hosp. Univ. 12 De Octubre**
Avda. Cordoba sn
Madrid
Spain
28041

**Study participating centre**
**Hosp. Univ. Germans Trias I Pujol**
Carretera de Canyet s/n
Badalona
Spain
8916

**Study participating centre**
**Hosp. De Manises**
Av. de la Generalitat Valenciana, 50
Valencia
Spain
46940

**Study participating centre**
**Hosp. Univ. De Cruces**
Plaza de Cruces, s/n
Barakaldo
Spain
48903

**Study participating centre**
**Hosp. Reina Sofia**
C/ Menéndez Pidal s/n
Córdoba
Spain
14004

**Study participating centre**
**Hosp. Univ. De Basurto**
Avenida de Montevideo, 18
Bilbao
Spain
48013

**Study participating centre**
**HIA Sainte Anne**
2 boulevard Sainte Anne
Toulon
France
83800

**Study participating centre**
**Hopital Charles Nicolle**
1 rue de Germont
Rouen
France
76031

**Study participating centre**
**Centre Hospitalier Le Mans**
194 Avenue Rubillard
Le Mans
France
72037

**Study participating centre**
**Guy's and St Thomas' NHS Foundation Trust**
Great Maze Pond
London
United Kingdom
SE1 9RT

**Study participating centre**
**University Hospital Southampton NHS Foundation Trust**
Tremona Road

Southampton
United Kingdom
SO16 6YD

**Study participating centre**
**Kume Clinic**
1-65-2, Otorihigashimachi, Nishi Ku
Osaka Fu
Japan
593-8324

**Study participating centre**
**Sapporo Skin Clinic**
2-1-1 Minami-3Jo Nishi
Sapporo
Japan
060-0063

**Study participating centre**
**Takagi Dermatology Clinic**
Nishi-sanjo Minami 4-16
Obihiro-shi
Japan
080-0013

**Study participating centre**
**Nomura Dermatology Clinic**
4-27-14 tanmachi
Yokohama
Japan
221-0825

**Study participating centre**
**Shizuoka Prefectural General Hospital**
4-27-1, Kitaando, Aoi-ku
Shizuoka
Japan
420-8527

**Study participating centre**
**Shirasaki Dermatology Clinic**
3-5-33 Ekinan
Takaoka
Japan
933-0871

**Study participating centre**
**Toyama Prefectural Central Hospital**
2-2-78 Nishinagae Toyama-shi
Toyama
Japan
930-8550

**Study participating centre**
**Seoul National University Bundang Hospital**
82, Gumi-ro 173beon-gil
Gyeonggi-do
Korea, South
13620

**Study participating centre**
**Konkuk University Medical Center**
120-1 NeunGdong-ro, Gwangjin-Gu
Seoul
Korea, South
5030

**Study participating centre**
**Pusan National University Hospital**
179 Gudeok-Ro
Busan
Korea, South
49241

**Study participating centre**
**KyungHee University Hospital**
23 Kyungheedae-Ro
Seoul
Korea, South
102-1703

**Study participating centre**
**Asan Medical Center**
88, Olympic-ro 43-gil, Songpa-gu,
Seoul
Korea, South
5505

**Study participating centre**
**Seoul National University Hospital**
101, Daehak-ro
Seoul
Korea, South
3080

**Study participating centre**
**Severance Hospital, Yonsei University Health System**
50-1, Yonsei-ro, Seodaemun-gu
Seoul
Korea, South
3722

**Study participating centre**
**WROMEDICA**
Mickiewicza 91
Wroclaw
Poland
51-685

**Study participating centre**
**DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.**
Tuberozy 3
Osielsko
Poland
86031

**Study participating centre**
**Nzoz Zdrowie Osteo-Medic**
ul. Wiejska 81

Bialystok
Poland
15-351

**Study participating centre**
**Dermed Centrum Medyczne Sp. z o.o**
ul. Piotrkowska 48
Lodz
Poland
90-265

**Study participating centre**
**Royalderm Agnieszka Nawrocka**
K.Kieślowskiego 3B/3
Warszawa
Poland
2962

**Study participating centre**
**Klinika Ambroziak Estederm Sp. z o.o**
Kosiarzy 9A
Warszawa
Poland
02-953

**Study participating centre**
**NZOZ Specderm**
Kardynala Stefana Wyszynskiego 10 lokal 11
Bialystok
Poland
15-888

**Study participating centre**
**Diamond Clinic Specjalistyczne Poradnie Lekarskie**
Stefana Rogozinskiego 6/U3
Krakow
Poland
31-559

**Study participating centre**
**National Taiwan University Hospital**
No.1, Changde Street
Taipei City
Taiwan
10048

**Study participating centre**
**Chang-Gung Memorial Hospital, LinKou Branch**
No.5 Fuxing street
Taoyuan
Taiwan
333

**Study participating centre**
**National Cheng Kung University Hospital**
138 Sheng-Li Rd
Tainan
Taiwan
704

**Study participating centre**
**Chang Gung Memorial Hospital**
Kaohsiung Branch
Kaohsiung
Taiwan
83342

**Study participating centre**
**Windsor Dermatology, PC**
59 One Mile Rd Ext Ste G
East Windsor
United States of America
8520

**Study participating centre**
**Arlington Dermatology**
5301 Keystone Ct.
Rolling Meadows
United States of America
60008

**Study participating centre**
**Modern Research Associates**
9101 N. Central Expressway
Dallas
United States of America
75231

**Study participating centre**
**Renstar Medical Research**
21 NE 1st Ave
Ocala
United States of America
34470

**Study participating centre**
**University of Pittsburgh Department of Dermatology**
3601 5th Ave
Pittsburgh
United States of America
15213

**Study participating centre**
**Forcare Clinical Research, Inc.**
15416 North Florida Avenue
Tampa
United States of America
33613

**Study participating centre**
**Indiana Clinical Trial Center**
824 Edwards Drive
Plainfield
United States of America
46168

**Study participating centre**
**Oregon Dermatology and Research Center**
2565 NW Lovejoy

Portland
United States of America
97210

**Study participating centre**
**Center for Clinical Studies**
1401 Binz Street
Houston
United States of America
77004

**Study participating centre**
**Center for Clinical Studies**
451 North Texas Avenue
Webster
United States of America
77598

**Study participating centre**
**Hamzavi Dermatology**
2950 Keewahdin Road
Fort Gratiot
United States of America
48059

**Study participating centre**
**Vivida Dermatology**
2110 East Flamingo Road, Suite 213
Las Vegas
United States of America
89119

**Study participating centre**
**Pacific Skin Institute**
1495 River Park Drive
Sacramento
United States of America
95815

### Study participating centre
**Synergy Clinical Research**
595 Buckingham Way
San Francisco
United States of America
94132

### Study participating centre
**Premier Clinical Research**
324 South Sherman
Spokane
United States of America
99202

## Sponsor information

### Organisation
Janssen (Belgium)

### Sponsor details
Janssen-Cilag International NV
Turnhoutseweg 30
Beerse
Belgium
2340
No telephone contact available
prderacta@prdgb.jnj.com

### Sponsor type
Industry

### Website
https://www.janssen.com/belgium/

### ROR
https://ror.org/04yzcpd71

## Funder(s)

### Funder type
Industry

### Funder Name
Janssen Research and Development

### Alternative Name(s)
Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

### Funding Body Type
Private sector organisation

### Funding Body Subtype
For-profit companies (industry)

### Location
United States of America

## Results and Publications

### Publication and dissemination plan
1. Peer-reviewed scientific journals
2. Study results will be available to participants via the provision of a Plain Language Summary at the end of the study and in addition results will be published in the EudraCT database

### Intention to publish date
13/11/2024

### Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are/will be available upon request. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinicaltrials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at yoda.yale.edu

### IPD sharing plan summary
Available on request

### Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | | | 28/06/2023 | No | No |
| Other unpublished results | Immunogenicity results have been redacted | | 09/08/2024 | No | No |